{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:02:34Z","timestamp":1759017754212,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Crutchfield Family Foundation"},{"DOI":"10.13039\/100011034","name":"Sidney Kimmel Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.leukres.2011.09.014","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T14:48:22Z","timestamp":1318862902000},"page":"363-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo"],"prefix":"10.1016","volume":"36","author":[{"given":"Luhong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.09.014_bib0005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2009.19","article-title":"D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy","volume":"23","author":"Wang","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.014_bib0010","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0015","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.014_bib0020","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1158\/1078-0432.CCR-07-4409","article-title":"A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.014_bib0025","first-page":"683","article-title":"Management of relapsed mantle cell lymphoma: still a treatment challenge","volume":"23","author":"Ruan","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.leukres.2011.09.014_bib0030","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/sj.leu.2404912","article-title":"Biological pathways and in vivo antitumor activity induced by atiprimod in myeloma","volume":"21","author":"Neri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.014_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2006.06.007","article-title":"Atiprimod: a multi-functional drug candidate for myeloid and other malignancies","volume":"31","author":"Shailubhai","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.014_bib0040","first-page":"111","article-title":"A phase I, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM)","volume":"106","author":"Wang","year":"2005","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.leukres.2011.09.014_bib0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.014_bib0050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0055","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.09.014_bib0060","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0065","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1182\/blood-2006-12-063958","article-title":"Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.014_bib0070","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3816\/CLML.2010.n.066","article-title":"Management of mantle cell lymphoma: key challenges and next steps","volume":"10","author":"Williams","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.leukres.2011.09.014_bib0075","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2018Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.09.014_bib0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Belch","year":"2007","journal-title":"Ann Oncol"},{"issue":"December 16","key":"10.1016\/j.leukres.2011.09.014_bib0095","article-title":"Mantle cell lymphoma: the promise of new treatment options","author":"Goy","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.09.014_bib0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.09.014_bib0110","first-page":"231","article-title":"SK&F 105685 suppresses allogenetically induced mononuclear and endothelial cell activation and cytokine production and prolongs rat cardiac allograft survival","volume":"24","author":"Hancock","year":"1992","journal-title":"Transplant Proc"},{"key":"10.1016\/j.leukres.2011.09.014_bib0115","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-3565(25)12696-7","article-title":"Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis","volume":"255","author":"Albrightson-Winslow","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2011.09.014_bib0120","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2004-09-3794","article-title":"(N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo","volume":"105","author":"Hamasaki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.014_bib0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/1535-7163.MCT-06-0561","article-title":"Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, atiprimod","volume":"6","author":"Choudhari","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2011.09.014_bib0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2005-01-0373","article-title":"A clinically relevant SCID-hu in vivo model of human multiple myeloma","volume":"106","author":"Tassone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.09.014_bib0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sj.bjc.6602637","article-title":"Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells","volume":"93","author":"Amit-Vazina","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2011.09.014_bib0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.leu.2404959","article-title":"Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo","volume":"22","author":"Wang","year":"2008","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611004577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:53Z","timestamp":1758934673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611004577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0145212611004577"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.09.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2011.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}